Skip to content
Research/Peptides/Adipotide (FTPP)

Adipotide (FTPP)

Adipotide is a peptide designed for treating obesity by targeting white adipose tissue through a dual-domain mechanism that induces endothelial cell apoptosis. Preclinical studies indicate its effectiveness in weight reduction and metabolic improvement, although dose-dependent nephrotoxicity raises safety concerns. Formulation strategies are being explored to enhance its therapeutic potential while minimizing off-target effects.

Intelligence Profile

Clinical Applications

No clinical evidence currently available. Our search of medical databases found no published clinical trials or research papers evaluating adipotide (FTPP) in human patients.

Without peer-reviewed clinical data, it is not possible to provide evidence-based information about:

  • Approved medical uses or indications
  • Clinical effectiveness for any conditions
  • Safety profile in human patients
  • Appropriate dosing or administration protocols

Adipotide appears to be an experimental compound that has not progressed to documented human clinical testing. Any claims about clinical applications would lack scientific substantiation at this time.


This information is for educational purposes only and should not be considered medical advice. Consult healthcare providers for guidance on approved treatments for specific medical conditions.

Free account required

Clinical data requires a free AXIFI account to access clinical data, safety profiles, and research papers.